Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: A population-based retrospective study

被引：59

作者：

Fjaerli H.-O. ^{[1
,2
]}

Farstad T. ^{[3
]}

Bratlid D. ^{[4
,5
]}

机构：

[1] University of Oslo, Oslo

[2] Faculty Division, Akershus University Hospital

[3] Department of Paediatrics, Akershus University Hospital

[4] Department of Laboratory Medicine, Norwegian Univ. of Sci./Technology, Trondheim

[5] Department of Paediatrics, St. Olav University Hospital, Trondheim

来源：

BMC Pediatrics | / 4卷 / 1期

关键词：

Congenital Heart Disease; Respiratory Syncytial Virus; Service Area; Palivizumab; Preterm Child;

D O I：

10.1186/1471-2431-4-25

中图分类号：

学科分类号：

摘要：

Background: RSV is recognized as the most important cause of serious lower respiratory tract illness in infants and young children worldwide leading to hospitalisation in a great number of cases, especially in certain high-risk groups. The aims of the present study were to identify risk groups, outcome and incidences of hospitalisation for RSV bronchiolitis in Norwegian children under two years of age and to compare the results with other studies. Methods: We performed a population-based retrospective survey for the period 1993-2000 in children under two years of age hospitalised for RSV bronchiolitis. Results: 822 admissions from 764 patients were identified, 93% had one hospitalisation, while 7% had two or more hospitalisations. Mean annual hospitalisation incidences were 21.7 per 1.000 children under one year of age, 6.8 per 1.000 children at 1-2 years of age and 14.1 per 1.000 children under two years of age. 77 children (85 admissions) belonged to one or more high-risk groups such as preterm birth, trisomy 21 and congenital heart disease. For preterm children under one year of age, at 1-2 years of age and under two years of age hospitalisation incidences per 1.000 children were 23.5, 8.7 and 16.2 respectively. The incidence for children under two years of age with trisomy 21 was 153.8 per 1.000 children. Conclusion: While the overall hospitalisation incidences and outcome of RSV bronchiolitis were in agreement with other studies, hospitalisation incidences for preterm children were lower than in many other studies. Age on admission for preterm children, when corrected for prematurity, was comparable to low-risk children. Length of hospitalisation and morbidity was high in both preterm children, children with a congenital heart disease and in children with trisomy 21, the last group being at particular high risk for severe disease. © 2004 Fjaerli et al; licensee BioMed Central Ltd.

引用

页数：7

共 22 条

[1] Law B.J., Carbonell-Estrany X., Simoes E.A., An update on respiratory syncytial virus epidemiology: A developed country perspective, Respiratory Medicine, 96, SUPPL. B, (2002)
[2] Henderson F.W., Collier A.M., Clyde W.A.J., Denny F.W., Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children, N. Engl. J. Med., 300, pp. 530-534, (1979)
[3] Constantopoulos A.G., Kafetzis D.A., Syrogiannopoulos G.A., Roilides E.J., Malaka-Zafiriu E.E., Sbyrakis S.S., Marcopoulos M.L., Burden of respiratory syncytial viral infections on paediatric hospitals: A two-year prospective epidemiological study, Eur. J. Clin. Microbiol. Infect. Dis., 21, pp. 102-107, (2002)
[4] Glezen W.P., Greenberg S.B., Atmar R.L., Piedra P.A., Couch R.B., Impact of respiratory virus infections on persons with chronic underlying conditions, Jama, 283, pp. 499-505, (2000)
[5] Fixler D.E., Respiratory syncytial virus infection in children with congenital heart disease: A review, Pediatr. Cardiol., 17, pp. 163-168, (1996)
[6] Stevens T.P., Sinkin R.A., Hall C.B., Maniscalco W.M., McConnochie K.M., Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: Hospitalization and economic implications of prophylaxis, Arch. Pediatr. Adolesc. Med., 154, pp. 55-61, (2000)
[7] Simoes E.A., Groothuis J.R., Respiratory syncytial virus prophylaxis - The story so far, Respir. Med., 96, SUPPL. B, (2002)
[8] Wren C.G., Bate B.J., Masters H.B., Lauer B.A., Detection of respiratory syncytial virus antigen in nasal washings by Abbott Test-Pack enzyme immunoassay, J. Clin. Microbiol., 28, pp. 1395-1397, (1990)
[9] Abels S., Nadal D., Stroehle A., Bossart W., Reliable detection of respiratory syncytial virus infection in children for adequate hospital infection control management, J. Clin. Microbiol., 39, pp. 3135-3139, (2001)
[10] Randolph A.G., Wang E.E., Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview, Arch. Pediatr. Adolesc. Med., 150, pp. 942-947, (1996)

← 1 2 3 →